Sai Life Sciences has released its unaudited standalone financial results for the quarter and six months ended September 30, 2025. The company reported revenue from operations of ₹5,266.69 million for the quarter. Profit before tax stood at ₹1,108.71 million, and profit after tax was ₹829.49 million. Earnings per share were reported as ₹3.97 (basic) and ₹3.89 (diluted) for the quarter. The results indicate sustained financial performance.
Financial Performance Overview
Sai Life Sciences announced its unaudited standalone financial results, highlighting key financial metrics for Q2 2026. The company’s performance reflects its position in the life sciences sector.
Key Financial Highlights (Standalone)
Key figures from the standalone financial results include:
- Revenue from operations: ₹5,266.69 million for the quarter.
- Other income: ₹149.33 million, bringing the total income to ₹5,416.02 million.
- Profit before tax: ₹1,108.71 million.
- Tax expense: ₹279.22 million.
- Profit for the period: ₹829.49 million.
- Earnings per share: ₹3.97 (basic) and ₹3.89 (diluted).
Six-Month Performance
For the six months ended September 30, 2025, the company’s revenue from operations was ₹10,097.07 million. Profit before tax was ₹1,888.53 million and profit after tax was ₹1,413.19 million.
Equity and Liabilities
The statement also provided insights into the company’s equity and liabilities:
- Equity share capital: ₹209.83 million.
- Other equity: ₹22,823.07 million.
- Total Equity: ₹23,032.90 million.
Cash Flow Highlights
- Net cash generated from operating activities: ₹788.68 million.
- Net cash used in investing activities: ₹(60.35) million.
- Net cash generated from financing activities: ₹388.17 million.
Additional Financial Details
The results reflect Sai Life Sciences’ financial activities and position up to September 30, 2025. The company’s management remains focused on growth within the pharmaceutical and life sciences industry.
Source: BSE
